

Abstract #1535: A Unique Model: Partnership Between Community Oncology and Pharma

Authors: Monica Lisi, BS; Laura Ensley, BS; Justin Adams, BS; Karen Poe, RN; Shikha Prakash, MBA; Lorraine Brisbin, MS, MLS – Precision Health Informatics | Karla Polk, BS – Bristol Myers Squibb | Kartik Konduri, MD; Scott Paulson, MD – Texas Oncology


Background

- Clinical trials are the foundation of oncologic drug development. Historically, only 23% of oncology trials are conducted in the community despite >70% of patients being treated this setting.
- Patients are hesitant to enroll in trials- in 2020, only 49% were willing, down from 85% in 2019. One way to improve this is participation by community oncologists, which allows patients to stay close to home.
- Precision Health Informatics (PHI) collaborated with Mirati Therapeutics to pilot a clinical trial enrichment program focused on increasing enrollment of patients in the community related to efficacy and outcomes of Adagrasib (KRAS G12C inhibitor) for NSCLC and CRC.

Methods

- This pilot was launched in 2021, with a prescreening study (DetECT) to find eligible patients with KRASG12C mutations.
- The pilot was then expanded across Mirati ‘Krystal’ studies in 2022 and to “1719” studies in 2023. These studies were available to all investigators throughout Texas Oncology (TxO) via STAR model.
- Eligible patients were identified from PHI’s proprietary molecular data warehouse (that stores molecular results for >400,000 patients treated at TxO).
- A data analyst identified patients with KRAS G12C mutation from the warehouse, and then cross-referenced patient-centric data in EMR to assess eligibility.

Site	DetECT 20422	Total Enrollment
DFW	x	20
Northeast Texas	x	6
Central/South Texas	x	4
San Antonio*	x	17
Gulf Coast*	x	5
West Texas	x	5
Distinct patients enrolled + C1D1		57



Conclusion


- This pilot demonstrates that community oncology can lead the way in clinical trial enrollment, even in early-phase targeted therapy studies.
- Community physicians can be engaged so patients can benefit from research participation close to home.
- This model shows that a diverse population was accrued and may serve as a blueprint to help Pharma satisfy the diversity requirements for clinical trials.
- PHI, with its molecular database, may partner with Pharma to identify targetable mutations and drive rapid trial enrollment for targeted therapies.




Results

- This collaboration resulted in the accrual of 118 patients and the engagement of 40 different Investigators across 8 different trials.
- 6 studies remain open across the Practice.
- 21 patients were enrolled on Krystal-001, 7 on Krystal-007, 10 on Krystal-010 and 56 on DetECT.
- Enrollment included patients from urban areas of DFW and rural populations in NE Texas, South and West Texas.
- In DetECT, TxO provided 84% of the total US enrollment, with a diverse population—54% white, 23% Hispanic, 12% black, and 9% Asian.
- Texas Oncology is the 2nd highest screening and enrolling site for Krystal’s studies.

Population Diversity in DetECT Trial



Number of patients Accrued on studies



For more information, please contact:
Lorraine.Brisbin@usoncology.com